|
| All patients | COX2 | p-value | Cyclin D1 | p-value | p21 | p-value | |||
| Low | High | Low | High | Low | High | |||||
| No. (%) | No. (%) | No. (%) | No. (%) | No. (%) | No. (%) | No. (%) | ||||
| Response | (N = 22) | (N = 1) | (N = 21) |
| (N = 7) | (N = 15) |
| (N = 16) | (N = 6) |
|
| PD | 8 (36.4%) | 1 (100%) | 7 (33.3%) | 0.608‡ | 2 (28.6%) | 6 (40%) | 0.451‡ | 6 (37.5%) | 2 (33.3%) | 0.170‡ |
| SD | 6 (27.3%) | 0 (0%) | 6 (28.6%) | 1 (14.3%) | 5 (33.3%) | 6 (37.5%) | 0 (0%) | |||
| PR | 3 (13.6%) | 0 (0%) | 3 (14.3%) | 1 (14.3%) | 2 (13.3%) | 2 (12.5%) | 1 (16.7%) | |||
| CR | 5 (22.7%) | 0 (0%) | 5 (23.8%) | 3 (42.9%) | 2 (13.3%) | 2 (12.5%) | 3 (50%) | |||
| Relapse | (N = 42) | (N = 28) | (N = 14) |
| (N = 27) | (N = 15) |
| (N = 15) | (N = 27) |
|
| Absent | 28 (66.7%) | 21 (75%) | 7 (50%) | 0.165‡ | 23 (85.2%) | 5 (33.3%) | 0.001‡ | 2 (13.3%) | 26 (96.3%) | <0.001‡ |
| Present | 14 (33.3%) | 7 (25%) | 7 (50%) | 4 (14.8%) | 10 (66.7%) | 13 (86.7%) | 1 (3.7%) | |||
| Relapse Free Survival | (N = 42) | (N = 28) | (N = 14) |
| (N = 27) | (N = 15) |
| (N = 15) | (N = 27) |
|
| Mean (months) (95%CI) | 28.49 months (25.52 - 31.46) | 30.31 months (27.03 - 33.59) | 24.86 months (19.30 - 30.41) | 0.092† | 31.93 months (29.03 - 34.83) | 22.27 months (17.12 - 27.41) | <0.001† | 18.13 months (13.85 - 22.42) | 34.19 months (32.62 - 35.75) | <0.001† |
| 12 month RFS | 85.7% | 89.3% | 78.6% | 88.9% | 80% | 60% | 100% | |||
| 24 month RFS | 69.1% | 78.6% | 50% | 85.2% | 40% | 20% | 96.3% | |||
| 30 month RFS | 66.4% | 74.8% | 50% | 85.2% | 32% | 13.3% | 96.3% | |||
| Death | (N = 60) | (N = 29) | (N = 31) |
| (N = 31) | (N = 29) |
| (N = 29) | (N = 31) |
|
| Alive | 40 (66.7%) | 25 (86.2%) | 15 (48.4%) | 0.002‡ | 26 (83.9%) | 14 (48.3%) | 0.003‡ | 9 (31%) | 31 (100%) | <0.001‡ |
| Died | 20 (33.3%) | 4 (13.8%) | 16 (51.6%) | 5 (16.1%) | 15 (51.7%) | 20 (69%) | 0 (0%) | |||
| Overall Survival | (N = 60) | (N = 29) | (N = 31) |
| (N = 31) | (N = 29) |
| (N = 29) | (N = 31) |
|
| Mean (months) (95%CI) | 26.85 months (23.92 - 29.79) | 31.90 months (29.06 - 34.74) | 22.12 months (17.69 - 26.54) | 0.001† | 31.06 months (27.90 - 34.23) | 22.41 months (17.93 - 26.90) | 0.003† | 17.93 months (13.75 - 22.11) | 35 months | <0.001† |
| 12 month OS | 73.3% | 93.1% | 54.8% | 87.1% | 58.6% | 44.8% | 100% | |||
| 24 month OS | 66.5% | 86.2% | 47.9% | 83.9% | 48.3% | 29.5% | 100% | |||
| 30 month OS | 66.5% | 86.2% | 47.9% | 83.9% | 48.3% | 29.5% | 100% | |||